Rachid Taoussi in Stable Condition After Malaria Hospitalization in Tanzania
According to converging reports, Taoussi has been hospitalized for the past four days and is receiving close medical attention.
Doctors say his condition is now 'relatively stable,' with some improvement in symptoms during the last day, added the reports. However, the medical team is still observing him and has not yet decided when he can leave the hospital.
Taoussi, who is currently the head coach of Tanzanian club Azam FC, reportedly felt a sudden decline in his health, which led to his hospitalization. Tests confirmed that he has malaria.
Rachid Taoussi is a well-known figure in African football and a former coach of Morocco's national team. Since taking over at Azam FC, he has been leading the team through a strong season. The club is currently in third place in the Tanzanian Premier League with 51 points.
Football fans across Morocco have been wishing Taoussi a full and speedy recovery.
Malaria is a serious disease caused by parasites that are spread through the bite of infected mosquitoes. It is common in many parts of Africa, Asia, and South America.
Malaria patients often suffer from high fever, chills, headaches, and tiredness. If not treated quickly, the illness can become very dangerous and even lead to death if not treated early.
Malaria is treatable, but it requires fast medical care. Doctors usually give special medicines to kill the parasites.
Travelers are advised to sleep under mosquito nets, use insect repellent, and wear long clothing, especially in the evening, to avoid getting malaria. In some cases, travelers also take preventive medicine before visiting high-risk areas. Tags: malariaRachid Taoussisports
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Morocco World
16 hours ago
- Morocco World
Casablanca's Oncorad Publishes 1st African Prostate Cancer Research in Leading U.S. Journal
Rabat – The Casablanca-based Oncorad Group has become the first cancer treatment center in Africa to publish research in 'Advances in Radiation Oncology,' in partnership with the American Society for Radiation Oncology (ASTRO). The featured study, carried out by Oncorad's research team at the Le Littoral Clinic, explores a combined treatment protocol for aggressive prostate cancer, integrating high-dose-rate (HDR) brachytherapy with external beam radiotherapy. Conducted on a cohort of more than 120 patients, including several international cases, the research demonstrated a 92% remission rate with no significant toxicity. These results are consistent with the highest global standards in cancer care. The project was developed by a multidisciplinary Moroccan team led by principal investigator Dr. Hamza Samlali and coordinated by Dr. Najlaa Assaid. The medical physics team included Youness Khobbaizi, Omar Hanicha, Mahdi Abou El Houda, and Sanaa Nabil, under the leadership of Professor Redouane Samlali, founder of Oncorad Group. The initiative also received academic support from Professor Hassan Jouhadi, head of oncology at the University Hospital of Casablanca and professor at the city's Faculty of Medicine. Read also: Oncorad Group Celebrates First Cryoablation Procedure in Morocco, North Africa This publication represents the largest clinical series of its kind from Africa and the MENA region and positions Oncorad as a leading regional actor in cancer treatment and research. The study's inclusion of international patients further underscores its transnational relevance. Beyond this achievement, Oncorad's research unit continues to pursue a wide range of projects focused on locally adapted, innovative cancer care solutions. These include advances in robotic surgery, state-of-the-art radiotherapy techniques, and investigations into the genetic and biological dimensions of cancer—all supported through collaborations with national and international partners. Advances in Radiation Oncology is globally recognized for promoting impactful clinical research, particularly from resource-limited settings. With an impact factor of 2.7 and listings in leading databases such as PubMed Central, Scopus, and Web of Science, the journal's publication of Oncorad's study marks a significant milestone for African contributions to global medical literature. By bringing African data and perspectives to the forefront of scientific dialogue, Oncorad aims to support the development of more inclusive, evidence-based treatment strategies that benefit cancer patients across low- and middle-income countries. Tags: HealthOncoradProstate Cancer
Morocco World
16 hours ago
- Morocco World
Morocco Jet Off to Kenya for CHAN 2024
The Moroccan national team for locally-based players will fly out to Nairobi next Sunday, July 27, aboard a special flight, ahead of the 2024 African Nations Championship (CHAN). Before departure, the Atlas Lions will play one final warm-up match behind closed doors against Burkina Faso this Thursday at 6pm, at the municipal stadium of Kenitra. Head coach Tarik Sektioui revealed his final squad list on July 23. Morocco have been drawn in Group A alongside hosts Kenya, Angola, Zambia, and DR Congo. The Moroccans will kick off their campaign on Sunday, August 3, against Angola at Nyayo Stadium. They'll then take on Kenya at the Moi International Sports Centre on August 10, before facing Zambia on August 14 at the same venue. Their final group stage clash will be on Sunday, August 17, against DR Congo – again at Nyayo Stadium. Sektioui will be hoping to guide the Atlas Cubs through a tricky group and emulate the triumphs of previous CHAN editions. Tags: Africa Cup of NationsCHANTarik Sektioui
Ya Biladi
2 days ago
- Ya Biladi
Mohammed VI Foundation and AstraZeneca partner to enhance rare disease care in Morocco
The Mohammed VI Foundation for Science and Health (FM6SS) and AstraZeneca signed a memorandum of understanding on Wednesday in Rabat to jointly develop Centers of Excellence for rare diseases, aiming to strengthen Morocco's healthcare ecosystem and improve care for patients affected by these conditions. This partnership is part of a broader initiative to provide innovative solutions to patients by facilitating earlier diagnosis, improving access to treatment, and enhancing training for healthcare professionals. It includes the development of advanced diagnostic platforms, the integration of cutting-edge technologies in genetic testing, and the creation of multidisciplinary hubs for care, research, and education. In a statement to MAP, Saber Boutayeb, Director of the Mohammed VI Center for Research and Innovation, said the agreement marks the culmination of a collaborative effort with AstraZeneca at the regional level, extending beyond Morocco. Rami Scandar, AstraZeneca's Regional President for the Near East and Maghreb, emphasized that the partnership is built around five key pillars. The first is reducing the average diagnostic time for rare diseases, which can currently take up to five years, thereby improving patient outcomes. The second involves creating genetic testing platforms in collaboration with the Foundation. The third pillar focuses on training doctors, nurses, and caregivers to strengthen support for patients with rare conditions. The fourth addresses equitable access to treatment by introducing medications priced appropriately for the Moroccan context, in coordination with the Ministry of Health. Finally, the fifth pillar seeks to improve epidemiological knowledge of rare diseases in Morocco through data collection and scientific monitoring. This agreement further reinforces AstraZeneca's long-term commitment to sustainable growth and partnership in Morocco. Building on previous successful collaborations with the Mohammed VI Foundation for Science and Health, the two parties are charting a shared path to address unmet medical needs and deliver a lasting, tangible impact for patients across the Kingdom.
